Caliper sheds jobs after Zymark buy
Caliper has cut 9 per cent of its staff as part of a restructuring
exercise following its $72 million acquisition of lab automation
Scancell, Celltech team up on new cancer target
Scancell and Celltech are to collaborate on the development of
novel monoclonal antibody therapeutics targeting Lewis y/b, a new
LION sells compound library to Norak
LION bioscience of Germany has sold a compound library consisting
of more than 500,000 diverse compounds to US company Norak
High throughput ion channel screening
Swedish biotech tools company Cellectricon says it has now received
orders from three of the top five pharmaceutical companies for its
Dynaflow microfluidic chip technology for increasing productivity
in the drug discovery process.
HIV vaccine trial raises hopes of developing world
The first vaccine targeting the strains of HIV prevalent in
sub-Saharan Africa and Asia, where millions of people are infected
with the virus, has started Phase I volunteer studies in the USA.
Researchers unravel LacY web
An Anglo-US team of researchers has unveiled the first structure of
a membrane transport protein; disruptions in the activity of MTPs
are involved in a number of diseases.
Roche takes crystal-clear route to development
Swiss drugmaker Roche has succeeded in developing a crystalline
form of one of its pipeline compounds with the help of a US
company, TransForm Pharmaceuticals, that is applying a
high-throughput approach to form and formulation.
LIT spectrometer pushes back sensitivity barrier
A linear ion trap (LIT) spectrometer that is up to 10 times more
sensitive than current systems will be launched later this year by
Applied Biosystems/MDS SCIEX
Qiagen sales accelerate on new product lines
Qiagen has reported strong growth in sales and profits in the
second quarter as last year's acquisitions of GenoVision and
Xeragon start to exert their effects. The company has also signed
two new deals in the area of RNA interference.
Angiogenesis conference set for September
A conference examining the progress made in the field of
angiogenesis inhibition,organised by SRI, will take place 29-30
September in Cambridge, Massachusetts.
Pharmagene says profitability is a realistic objective
Pharmagene has reported a near-doubling in turnover in the first
half of this year, on the back of strong growth in its drug
discovery services division.
Dharmacon gets US RNAi patent
Dharmacon has been awarded a US Patent (No 6,590,093) which covers
its proprietary 2'-ACE chemistry for the production of synthetic
Takeda strikes deals to boost pipeline
Takeda signs two new research collaborations in the areas of
Alzheimer's disease and antibody-based drugs, in a move to bolster
its product pipeline.
GPC says anti-MHC antibody is nearing clinic
GPC reports progress with its anti-MHC class II antibody, with
potential in a range of haematological malignancies, and says it
now has sufficient quantities to start a clinical trials programme.
Pfizer pulls out of Phytopharm collaboration
Botanical drug specialist Phytopharm suffered a setback yesterday
when Pfizer withdrew from a collaboration to develop P57, a drug
for obesity and metabolic syndrome.